Recent pharmacological advances in paediatric analgesics

Biomedicine and Pharmacotherapy

Volumn 60, Issue 7, 2006, Pages 303-309

  Anderson, B J ^a   Palmer, G M ^b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Analgesia; Paediatrics; Pharmacokinetics

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACYLTRANSFERASE; AMIDE; AMINOGLYCOSIDE; ANALGESIC AGENT; BENZODIAZEPINE DERIVATIVE; BUPIVACAINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DICLOFENAC; IBUPROFEN; KETAMINE; KETOROLAC; LEVOBUPIVACAINE; LOCAL ANESTHETIC AGENT; MORPHINE; MORPHINE 3 GLUCURONIDE; NITRIC OXIDE DONOR; NITROUS OXIDE; NITROXYPARACETAMOL; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROPACETAMOL; ROPIVACAINE; SEDATIVE AGENT; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOMETRY; AMNESIA; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BINDING AFFINITY; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSTIPATION; CONTACT DERMATITIS; DISEASE EXACERBATION; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG HALF LIFE; DRUG METABOLISM; DYSPHORIA; EXPERIMENTAL RAT; GENETIC DIFFERENCE; HALLUCINATION; HUMAN; HYPNOSIS; INJECTION PAIN; INTENSIVE CARE UNIT; INTRACRANIAL PRESSURE; LIVER INJURY; NAUSEA; NONHUMAN; NOSE DISEASE; PATENT DUCTUS ARTERIOSUS; PEDIATRIC ANESTHESIA; PEROPERATIVE CARE; PHARMACODYNAMICS; PHARMACOGENOMICS; POSTOPERATIVE ANALGESIA; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESPIRATORY TRACT DISEASE; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS; VOMITING;

ACETAMINOPHEN; ANALGESICS; CHILD; HUMANS; KETAMINE; MORPHINE; NITROUS OXIDE; TRAMADOL;

EID: 33747882585     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2006.06.014     Document Type: Article

References (95)

1. Walker S.M. Management of procedural pain in NICUs remains problematic. Paediatr. Anaesth. 15 (2005) 909-912
2. Anderson B.J., and Meakin G.H. Scaling for size: some implications for paediatric anaesthesia dosing. Paediatr. Anaesth. 12 (2002) 205-219
3. Meibohm B., Laer S., Panetta J.C., and Barrett J.S. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7 (2005) E475-E487
4. Baber N., and Pritchard D. Dose estimation for children. Br. J. Clin. Pharmacol. 56 (2003) 489-493
5. Bjorkman S. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children: how accurate are available scaling methods?. Clin. Pharmacokinet. 45 (2006) 1-11
6. Holford N.H.G. A size standard for pharmacokinetics. Clin. Pharmacokinet. 30 (1996) 329-332
7. Dawson W.T. Relations between age and weight and dosages of drugs. Ann. Intern. Med. 13 (1940) 1594-1613
8. West G.B., Brown J.H., and Enquist B.J. A general model for the origin of allometric scaling laws in biology. Science 276 (1997) 122-126
9. West G.B., Brown J.H., and Enquist B.J. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 284 (1999) 1677-1679
10. Allegaert K., Van der Marel C.D., Debeer A., Pluim M.A., Van Lingen R.A., Vanhole C., et al. Pharmacokinetics of single dose intravenous propacetamol in neonates: effect of gestational age. Arch. Dis. Child. Fetal Neonatal Ed. 89 (2004) F25-F28
11. Anderson B.J., Pons G., Autret-Leca E., Allegaert K., and Boccard E. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis. Paediatr. Anaesth. 15 (2005) 282-292
12. Wurthwein G., Koling S., Reich A., Hempel G., Schulze-Westhoff P., Pinheiro P.V., et al. Pharmacokinetics of intravenous paracetamol in children and adolescents under major surgery. Eur. J. Clin. Pharmacol. 60 (2005) 883-888
13. Anderson B.J., Woollard G.A., and Holford N.H. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur. J. Clin. Pharmacol. 57 (2001) 559-569
14. Allegaert K., Anderson B.J., Naulaers G., de Hoon J., Verbesselt R., Debeer A., et al. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates. Eur. J. Clin. Pharmacol. 60 (2004) 191-197
15. Murat I., Baujard C., Foussat C., Guyot E., Petel H., Rod B., et al. Tolerance and analgesic efficacy of a new i.v. paracetamol solution in children after inguinal hernia repair. Paediatr. Anaesth. 15 (2005) 663-670
16. van der Marel C.D., Anderson B.J., Pluim M.A., de Jong T.H., Gonzalez A., and Tibboel D. Acetaminophen in cerebrospinal fluid in children. Eur. J. Clin. Pharmacol. 59 (2003) 297-302
17. Allegaert K., Verbesselt R., Devlieger H., de Hoon J., and Tibboel D. Cerebrospinal fluid pharmacokinetics of paracetamol after intravenous propacetamol in a former preterm infant. Br. J. Clin. Pharmacol. 57 (2004) 224-225
18. Moore P.K., and Marshall M. Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig. Liver Dis. 35 Suppl 2 (2003) S49-S60
19. Gaitan G., Ahuir F.J., and Herrero J.F. Enhancement of fentanyl antinociception by subeffective doses of nitroparacetamol (NCX-701) in acute nociception and in carrageenan-induced monoarthritis. Life Sci. 77 (2005) 85-95
20. Futter L.E., al-Swayeh O.A., and Moore P.K. A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br. J. Pharmacol. 132 (2001) 10-12
21. Wallace J.L. Acetaminophen hepatotoxicity: NO to the rescue. Br. J. Pharmacol. 143 (2004) 1-2
22. Fiorucci S., Antonelli E., Distrutti E., Mencarelli A., Farneti S., Del Soldato P., et al. Liver delivery of NO by NCX-1000 protects against acute liver failure and mitochondrial dysfunction induced by APAP in mice. Br. J. Pharmacol. 143 (2004) 33-42
23. Aranda J.V., Varvarigou A., Beharry K., Bansal R., Bardin C., Modanlou H., et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 86 (1997) 289-293
24. Van Overmeire B., Touw D., Schepens P.J., Kearns G.L., and van den Anker J.N. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin. Pharmacol. Ther. 70 (2001) 336-343
25. Scott C.S., Retsch-Bogart G.Z., Kustra R.P., Graham K.M., Glasscock B.J., and Smith P.C. The pharmacokinetics of ibuprofen suspension, chewable tablets, and tablets in children with cystic fibrosis. J. Pediatr. 134 (1999) 58-63
26. Smyth J.M., Collier P.S., Darwish M., Millership J.S., Halliday H.L., Petersen S., et al. Intravenous indometacin in preterm infants with symptomatic patent ductus arteriosus. A population pharmacokinetic study. Br. J. Clin. Pharmacol. 58 (2004) 249-258
27. Topic E., Stefanovic M., and Samardzija M. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Clin. Chem. Lab. Med. 42 (2004) 72-78
28. Garcia-Martin E., Martinez C., Tabares B., Frias J., and Agundez J.A. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin. Pharmacol. Ther. 76 (2004) 119-127
29. Tanaka E. Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. J. Clin. Pharm. Ther. 23 (1998) 403-416
30. Pariente-Khayat A., Rey E., Gendrel D., Vauzelle-Kervroedan F., Cremier O., d'Athis P., et al. Isoniazid acetylation metabolic ratio during maturation in children. Clin. Pharmacol. Ther. 62 (1997) 377-383
31. Allegaert K., Anderson B.J., Verbesselt R., Debeer A., de Hoon J., Devlieger H., et al. Tramadol disposition in the very young: an attempt to assess in vivo cytochrome P-450 2D6 activity. Br. J. Anaesth. 95 (2005) 231-239
32. Kearns G.L., Robinson P.K., Wilson J.T., Wilson-Costello D., Knight G.R., Ward R.M., et al. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny. Clin. Pharmacol. Ther. 74 (2003) 312-325
33. Gregoire N., Gualano V., Geneteau A., Millerioux L., Brault M., Mignot A., et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J. Clin. Pharmacol. 44 (2004) 1114-1124
34. Jackson I.D., Heidemann B.H., Wilson J., Power I., and Brown R.D. Double-blind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. Br. J. Anaesth. 92 (2004) 675-680
35. Gaitan G., and Herrero J.F. Subanalgesic doses of dexketoprofen and HCT-2037 (nitrodexketoprofen) enhance fentanyl antinociception in monoarthritic rats. Pharmacol. Biochem. Behav. 80 (2005) 327-332
36. van der Marel C.D., Anderson B.J., Romsing J., Jacqz-Aigrain E., and Tibboel D. Diclofenac and metabolite pharmacokinetics in children. Paediatr. Anaesth. 14 (2004) 443-451
37. Palmer G.M. A teenager with severe asthma exacerbation following ibuprofen. Anaesth. Intensive Care 33 (2005) 261-265
38. Allegaert K., Cossey V., Langhendries J.P., Naulaers G., Vanhole C., Devlieger H., et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol. Neonate 86 (2004) 207-211
39. Allegaert K., Cossey V., Debeer A., Langhendries J.P., Van Overmeire B., de Hoon J., et al. The impact of ibuprofen on renal clearance in preterm infants is independent of the gestational age. Pediatr. Nephrol. 20 (2005) 740-743
40. Allegaert K., Anderson B.J., Cossey V., and Holford N.H. Limited predictability of amikacin clearance in extreme premature neonates at birth. Br. J. Clin. Pharmacol. 61 (2005) 39-48
41. Gupta A., Daggett C., Drant S., Rivero N., and Lewis A. Prospective randomized trial of ketorolac after congenital heart surgery. J. Cardiothorac. Vasc. Anesth. 18 (2004) 454-457
42. Moffett B.S., Wann T.I., Carberry K.E., and Mott A.R. Safety of ketorolac in neonates and infants after cardiac surgery. Paediatr. Anesth. 16 (2006) 424-428
43. Ment L.R., Vohr B.R., Makuch R.W., Westerveld M., Katz K.H., Schneider K.C., et al. Prevention of intraventricular hemorrhage by indomethacin in male preterm infants. J. Pediatr. 145 (2004) 832-834
44. Cardwell M., Siviter G., and Smith A. Non-steroidal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst. Rev. (2005) April 18; (2) CD003591
45. Sheeran P.W., Rose J.B., Fazi L.M., Chiavacci R., and McCormick L. Rofecoxib administration to paediatric patients undergoing adenotonsillectomy. Paediatr. Anaesth. 14 (2004) 579-583
46. Joshi W., Connelly N.R., Reuben S.S., Wolckenhaar M., and Thakkar N. An evaluation of the safety and efficacy of administering rofecoxib for postoperative pain management. Anesth. Analg. 97 (2003) 35-38
47. Jones S.F., and Power I. Editorial I: postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Br. J. Anaesth. 95 (2005) 281-284
48. Krotz F., Schiele T.M., Klauss V., and Sohn H.Y. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res. 42 (2005) 312-324
49. West P.M., and Fernandez C. Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity. Ann. Pharmacother. 37 (2003) 1497-1501
50. Levin R.I. Theriac found? Nitric oxide-aspirin and the search for the universal cure. J. Am. Coll. Cardiol. 44 (2004) 642-643
51. Zwaveling J., Bubbers S., van Meurs A.H., Schoemaker R.C., van Heel I.R., Vermeij P., et al. Pharmacokinetics of rectal tramadol in postoperative paediatric patients. Br. J. Anaesth. 93 (2004) 224-227
52. van den Berg A.A., Halliday E., Lule E.K., and Baloch M.S. The effects of tramadol on postoperative nausea, vomiting and headache after ENT surgery. A placebo-controlled comparison with equipotent doses of nalbuphine and pethidine. Acta Anaesthesiol. Scand. 43 (1999) 28-33
53. Scott L.J., and Perry C.M. Tramadol: a review of its use in perioperative pain. Drugs 60 (2000) 139-176
54. Bozkurt P. Use of tramadol in children. Pediatric Anesthesia 15 (2005) 1041-1047
55. Khosravi M.B., Khezri S., and Azemati S. Tramadol for pain relief in children undergoing herniotomy: a comparison with ilioinguinal and iliohypogastric blocks. Paediatr. Anaesth. 16 (2006) 54-58
56. Hullett B.J., Chambers N.A., Pascoe E.M., and Johnson C. Tramadol vs. morphine during adenotonsillectomy for obstructive sleep apnea in children. Pediatr. Anesth. 16 (2006) 648-653
57. Enggaard T.P., Poulsen L., Arendt-Nielsen L., Brosen K., Ossig J., and Sindrup S.H. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth. Analg. 102 (2006) 146-150
58. Poulsen L., Arendt-Nielsen L., Brosen K., and Sindrup S.H. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther. 60 (1996) 636-644
59. Payne K.A., Roelofse J.A., and Shipton E. Pharmacokinetics of oral tramadol drops for postoperative pain relief in children aged 4 to 7 years-a pilot study. Anesth. Prog. 49 (2002) 109-112
60. Anand K.J., Barton B.A., McIntosh N., Lagercrantz H., Pelausa E., Young T.E., et al. Analgesia and sedation in preterm neonates who require ventilatory support: results from the NOPAIN trial. Neonatal Outcome and Prolonged Analgesia in Neonates. Arch. Pediatr. Adolesc. Med. 153 (1999) 331-338
61. Anand K.J., Hall R.W., Desai N., Shephard B., Bergqvist L.L., Young T.E., et al. Effects of morphine analgesia in ventilated preterm neonates: primary outcomes from the NEOPAIN randomised trial. Lancet 363 (2004) 1673-1682
62. Hall R.W., Kronsberg S.S., Barton B.A., Kaiser J.R., and Anand K.J. Morphine, hypotension, and adverse outcomes among preterm neonates: who's to blame? Secondary results from the NEOPAIN trial. Pediatrics 115 (2005) 1351-1359
63. Bouwmeester N.J., Anderson B.J., Tibboel D., and Holford N.H. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92 (2004) 208-217
64. Chay P.C., Duffy B.J., and Walker J.S. Pharmacokinetic-pharmacodynamic relationships of morphine in neonates. Clin. Pharmacol. Ther. 51 (1992) 334-342
65. Bouwmeester N.J., van den Anker J.N., Hop W.C., Anand K.J., and Tibboel D. Age- and therapy-related effects on morphine requirements and plasma concentrations of morphine and its metabolites in postoperative infants. Br. J. Anaesth. 90 (2003) 642-652
66. Stamer U.M., Bayerer B., and Stuber F. Genetics and variability in opioid response. Eur. J. Pain 9 (2005) 101-104
67. Lotsch J., Skarke C., Liefhold J., and Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 43 (2004) 983-1013
68. Ikeda K., Ide S., Han W., Hayashida M., Uhl G.R., and Sora I. How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol. Sci. 26 (2005) 311-317
69. Berde C. Convulsions associated with pediatric regional anesthesia. Anesth. Analg. 75 (1992) 164-166
70. Frawley G.P., Downie S., and Huang G.H. Levobupivacaine caudal anaesthesia in children: a randomised double blind comparison with bupivacaine. Pediatr. Anesth. 16 (2006) 754-760
71. Ivani G., De Negri P., Lonnqvist P.A., L'Erario M., Mossetti V., Difilippo A., et al. Caudal anesthesia for minor pediatric surgery: a prospective randomized comparison of ropivacaine 0.2% vs. levobupivacaine 0.2%. Paediatr. Anaesth. 15 (2005) 491-494
72. De Negri P., Ivani G., Tirri T., Modano P., Reato C., Eksborg S., et al. A comparison of epidural bupivacaine, levobupivacaine, and ropivacaine on postoperative analgesia and motor blockade. Anesth. Analg. 99 (2004) 45-48
73. Chalkiadis G.A., and Anderson B.J. Age and size are the major covariates for prediction of levobupivacaine clearance in children. Paediatr. Anaesth. 16 (2006) 275-282
74. Rapp H.J., Molnar V., Austin S., Krohn S., Gadeke V., Motsch J., et al. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block. Paediatr. Anaesth. 14 (2004) 724-732
75. Bosenberg A.T., Thomas J., Lopez T., Huledal G., Jeppsson L., and Larsson L.E. Plasma concentrations of ropivacaine following a single-shot caudal block of 1, 2 or 3 mg/kg in children. Acta Anaesthesiol. Scand. 45 (2001) 1276-1280
76. Dalens B., Ecoffey C., Joly A., Giaufre E., Gustafsson U., Huledal G., et al. Pharmacokinetics and analgesic effect of ropivacaine following ilioinguinal/iliohypogastric nerve block in children. Paediatr. Anaesth. 11 (2001) 415-420
77. Bosenberg A.T., Thomas J., Cronje L., Lopez T., Crean P.M., Gustafsson U., et al. Pharmacokinetics and efficacy of ropivacaine for continuous epidural infusion in neonates and infants. Paediatr. Anaesth. 15 (2005) 739-749
78. Anderson B.J., and Hansen T.G. Getting the best from pediatric pharmacokinetic data. Paediatr. Anaesth. 14 (2004) 713-715
79. Fredriksson A., Archer T., Alm H., Gordh T., and Eriksson P. Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. Behav. Brain Res. 153 (2004) 367-376
80. Wang C., Sadovova N., Fu X., Schmued L., Scallet A., Hanig J., et al. The role of the N-methyl-d-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. Neuroscience 132 (2005) 967-977
81. Soriano S.G., Anand K.J., Rovnaghi C.R., and Hickey P.R. Of mice and men: should we extrapolate rodent experimental data to the care of human neonates?. Anesthesiology 102 (2005) 866-868
82. Anand K.J., and Soriano S.G. Anesthetic agents and the immature brain: are these toxic or therapeutic?. Anesthesiology 101 (2004) 527-530
83. Davidson A., and Soriano S. Does anaesthesia harm the developing brain-evidence or speculation?. Paediatr. Anaesth. 14 (2004) 199-200
84. Young C., Jevtovic-Todorovic V., Qin Y.Q., Tenkova T., Wang H., Labruyere J., et al. Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. Br. J. Pharmacol. 146 (2005) 189-197
85. Lin C., and Durieux M.E. Ketamine and kids: an update. Paediatr. Anaesth. 15 (2005) 91-97
86. Becke K., Albrecht S., Schmitz B., Rech D., Koppert W., Schuttler J., et al. Intraoperative low-dose S-ketamine has no preventive effects on postoperative pain and morphine consumption after major urological surgery in children. Paediatr. Anaesth. 15 (2005) 484-490
87. Subramaniam K., Subramaniam B., and Steinbrook R.A. Ketamine as adjuvant analgesic to opioids: a quantitative and qualitative systematic review. Anesth. Analg. 99 (2004) 482-495
88. Tsui B.C., Davies D., Desai S., and Malherbe S. Intravenous ketamine infusion as an adjuvant to morphine in a 2-year-old with severe cancer pain from metastatic neuroblastoma. J. Pediatr. Hematol. Oncol. 26 (2004) 678-680
89. Himmelseher S., and Durieux M.E. Revising a dogma: ketamine for patients with neurological injury?. Anesth. Analg. 101 (2005) 524-534 (table of contents)
90. Ekbom K., Jakobsson J., and Marcus C. Nitrous oxide inhalation is a safe and effective way to facilitate procedures in paediatric outpatient departments. Arch. Dis. Child. 90 (2005) 1073-1076
91. Burnweit C., Diana-Zerpa J.A., Nahmad M.H., Lankau C.A., Weinberger M., Malvezzi L., et al. Nitrous oxide analgesia for minor pediatric surgical procedures: an effective alternative to conscious sedation?. J. Pediatr. Surg. 39 (2004) 495-499 (discussion 495-9)
92. Fishman G., Botzer E., Marouani N., and DeRowe A. Nitrous oxide-oxygen inhalation for outpatient otologic examination and minor procedures performed on the uncooperative child. Int. J. Pediatr. Otorhinolaryngol. 69 (2005) 501-504
93. Babl F.E., Puspitadewi A., Barnett P., Oakley E., and Spicer M. Preprocedural fasting state and adverse events in children receiving nitrous oxide for procedural sedation and analgesia. Pediatr. Emerg. Care 21 (2005) 736-743
94. Williams D.G., Patel A., and Howard R.F. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 89 (2002) 839-845
95. Flores C.M., and Mogil J.S. The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics 2 (2001) 177-194